Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed a 15% revenue increase and improved gross margins, but the company still reported a net loss. The lack of strategic initiatives and forward-looking guidance, coupled with a 5% rise in operating expenses, tempers the positive financial metrics. The acknowledgment of risks without specific mitigation strategies adds uncertainty. Overall, the mixed financial performance and absence of strategic discussion suggest a neutral sentiment.
Key Financial Performance
Revenue Revenue for Q4 2025 was $5.2 million, representing a 15% increase year-over-year. This growth was driven by higher sales volume and increased adoption of the company's technology.
Gross Margin Gross margin improved to 65% in Q4 2025, up from 60% in the same period last year. The improvement was attributed to better cost management and operational efficiencies.
Net Loss Net loss for Q4 2025 was $2.8 million, compared to $3.5 million in Q4 2024. The reduction in net loss was due to increased revenue and improved gross margin.
Operating Expenses Operating expenses were $4.5 million in Q4 2025, a 5% increase year-over-year. The increase was primarily due to higher R&D investments and marketing expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those implied. This includes risks related to financial performance, position, and the efficacy of Profound technology.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors PM
Benjamin Haynor
Border Advisors
CEO Tamberrino
Capital Inc
Chairman CEO
Chief Commercial
Commercial Officer
Dewan Chief
Division Freeman
Division McAulay
Division Potter
Division Scott
EST day
Financial Results
Freeman Raymond
Haynor Lake
Instructions today
Lake Street
Ltd Research
Markets LLC
McAulay Stifel
McAuley Paradigm
Medical Financial
Northern Border
Officer Benjamin
Officer Chairman
Paradigm Capital
Potter Northern
Profound Medical
Raymond Ltd
Research Division
COO Transcript
The Cooper Companies, Inc. (COO) Q2 2026 Earnings Call Transcript
Neutral6-5
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Unknown3-6
The earnings call revealed a 15% revenue increase and improved gross margins, but the company still reported a net loss. The lack of strategic initiatives and forward-looking guidance, coupled with a 5% rise in operating expenses, tempers the positive financial metrics. The acknowledgment of risks without specific mitigation strategies adds uncertainty. Overall, the mixed financial performance and absence of strategic discussion suggest a neutral sentiment.
The Cooper Companies, Inc. (COO) Q1 2026 Earnings Call Transcript
Positive3-6
The earnings call highlights strong financial performance with a 7% revenue increase and 8% EPS growth. Despite a slight decrease in gross margin, operating margins remain stable. Positive projections for revenue and margin improvements, alongside strategic growth in contact lens and fertility segments, contribute to a positive outlook. The absence of discussed risks and stable capital expenditures further support this sentiment. However, the lack of specific shareholder return plans slightly tempers the overall positivity.
The Cooper Companies, Inc. (COO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
COO Slides
COO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
